Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
- Primary completion Nov 23, 2026Sponsor estimatePhase 2NCT06567782A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III...GlaxoSmithKline · Neoplasms, ColonRecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 24, 2026Sponsor estimatePhase 1/Phase 2NCT06267729Study of AZD0754 in Participants With Metastatic Prostate CancerAstraZeneca · Metastatic Prostate CancerRecruitingAZNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsMemorial Sloan Kettering Cancer Center · Rectal AdenocarcinomaRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06063850AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyUniQure Biopharma B.V. · Mesial Temporal Lobe EpilepsyRecruitingQURELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06643884Suprachoroidal Administration in Subjects With Metastases to the ChoroidAura Biosciences · Eye CancerRecruitingAURALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06812078A Study of TAK-360 in Adults With Idiopathic HypersomniaTakeda · Idiopathic HypersomniaRecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 1/Phase 2NCT06840119Phase 1/2 Study of IMC-R117C in Selected Advanced CancersImmunocore Ltd · CancerRecruitingIMCRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimatePhase 2NCT06952699A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)Takeda · Narcolepsy Type 2RecruitingTAKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03340129Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)Melanoma Institute Australia · Melanoma Stage IvRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT03740893PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response...Institute of Cancer Research, United Kingdom · Breast NeoplasmRecruitingAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04204837Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinSalzburger Landeskliniken · Squamous Cell Carcinoma of the SkinRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT04912765Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRCNational Cancer Centre, Singapore · Hepatocellular CarcinomaRecruitingBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT04990102Phase IB/II of CPX-351 for Relapse Prevention in AMLGeorgetown University · Acute Myeloid Leukemia (AML) in RemissionRecruitingJAZZCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05024097A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After...Weill Medical College of Cornell University · Rectal CancerRecruitingRCUSCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2/Phase 3NCT05065216Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)DiaMedica Therapeutics Inc · Acute StrokeRecruitingDMACLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05147467Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLAscentage Pharma Group Inc. · Chronic Lymphocytic LeukemiaRecruitingAAPGLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05182164Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasInstitut Bergonié · Soft Tissue Sarcoma AdultRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05263050Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine TumorsFox Chase Cancer Center · Metastatic Renal Cell CarcinomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05425004Cabozantinib for Patients With Recurrent or Progressive MeningiomaBaptist Health South Florida · MeningiomaRecruitingEXELCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaLantern Pharma Inc. · Adenocarcinoma of LungRecruitingLTRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05608681A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE).Eupraxia Pharmaceuticals Inc. · Eosinophilic EsophagitisRecruitingEPRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05718323Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCETOP IBCSG Partners Foundation · SCLC,Extensive StageRecruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT05784688Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsTiumBio Co., Ltd. · Solid TumorRecruitingMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05800275Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal DiseaseUNICANCER · Leptomeningeal MetastasisRecruitingPFECollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05871970Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18...Protara Therapeutics · Lymphatic MalformationRecruitingTARALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 129 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.